Atlanta, GA - (NewMediaWire) - January 04, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.

Presentation Details:

Presenter:          David Dodd, Chairman & CEO

Date/Time:        January 9, 2023, 5:00 pm PST

Location:          Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA

Website:            https://informaconnect.com/biotech-showcase/registration-options/

A webcast of the presentation will be available at the following link: https://event.webcasts.com/starthere.jsp?ei=1590568&tp_key=ddac005afe

Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:

●      Biotech Showcase partnering platform: https://informaconnect.com/biotech-showcase/

●      Biotechnology Innovation Organization (BIO) partnering platform: https://www.bio.org/events/bio-partnering-jpm

●      Direct outreach to the Company at info@geovax.com or to its Investor Relations at govx@cg.capital

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Media Relations Contact:

Gina Cestari

6 Degrees

917-797-7904

gcestari@6degreespr.com

Investor Relations Contact:

Rich Cockrell

CG Capital

404-736-3838

govx@cg.capital

View the original release on www.newmediawire.com